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Dementia is a worldwide health problem which affects millions of patients; Alzheimer’s
disease (AD) and subcortical vascular dementia (sVAD) are the two most frequent forms
of its presentation. As no definite therapeutic options have been discovered, different risk
factors for cognitive impairment have been searched for potential therapies. This report
focuses on the possible evidence that vitamin D deficiency and hyper-homocysteinemia
can be considered as two important factors for the development or the progression of
neurodegenerative or vascular pathologies. To this end, we assessed: the difference in
vascular risk factors and vitamin D-OH25 levels among groups of sVAD, AD, and healthy
age-matched controls; the association of folate, B12, homocysteine, and vitamin D with
sVAD/AD and whether a deficiency of vitamin D and an increment in homocysteine levels
may be related to neurodegenerative or vessel damages. The commonly-considered
vascular risk factors were collected in 543 patients and compared with those obtained
from a healthy old volunteer population. ANOVA group comparison showed that vitamin
D deficiency was present in demented cases, as well as low levels of folate and high
levels of homocysteine, more pronounced in sVAD cases. The statistical models we
employed, with regression models built, and adjustments for biochemical, demographic
and neuropsychiatric scores, confirmed the association between the three measures
(folate decrease, hyperhomocysteinemia and vitamin D decrease) and dementia, more
pronounced in sVAD than in AD.
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INTRODUCTION
Dementia is a major clinical condition, which increases in prevalence and incidence, more rapidly
with advancing age. The consequence is the macroscopic alteration of the daily living abilities.
However, the different types of dementia have various causes and pathogenesis (Reitz et al.,
2011). It is accepted that many cerebrovascular alterations coexist or are determinant even in
neurodegenerative disorders such as AD, and the two different conditions share many different
risk factors (Jellinger, 2013).
Whereas, the operative definition of AD is established, it is more difficult to define the criteria
for subcortical vascular dementia, which is a clinical entity related to small vessel muscle cells
disease with consequent hypo-perfusion, diffuse ischemic white matter lesions, and incomplete
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ischemic damage (Rockwood, 2003; Korczyn et al., 2012;
Jellinger, 2013). These are more frequently localized in the white
matter, basal ganglia, thalamus and pons, with surrounding
astrocytes and oligodendrocytes (Chui, 2001; Moretti et al.,
2005). Clinical characteristic features of sVAD are progressive
signs of a dysexecutive syndrome, reduced planning, and
cognitive flexibility, decreased processing speed, and behavior
alterations, such as depression and apathy (Meyer et al., 2000;
Moretti et al., 2011; Roh and Lee, 2014; Shi and Wardlaw, 2016).
Risk factors have been debated in dementia, especially
metabolic features, hormonal changes, and vitamin alterations;
these aspects have been related to a molecular pathogenesis in all
the forms of cognitive decline, and hopefully, to a more effective
management. Therefore, the target of many investigations has
been to identify nutrition and lifestyle-based risk factors related
to dementia, in order to develop possible future primary
prevention efforts (Karakis et al., 2016). Many studies have been
devoted to the increase of homocysteine, due to low folate and
vitamin B12 deficiency in cognitive altered process; these studies
focused on homocysteine effects on endothelium and neuronal
disruption acting as a promoter of neurodegenerative events
(Nelson et al., 2016; Smith and Refsum, 2016), but results are
quite confounding, sometimes puzzling, and unclear (Malouf
and Grimley Evans, 2008; Hainsworth et al., 2016; Moretti et al.,
2017).
In the recent years, an increasing evidence supports a role
for the fat-soluble vitamin D in brain function and development
(Holick, 2004; McGrath et al., 2004; Schlogl and Holick, 2014;
Granic et al., 2015). Vitamin D deficiency has been related with
AD due to (1) a neurodegenerative accelerating property (Afzal
et al., 2014; Prabhakar et al., 2015); (2) vascular acute damage,
due to a presumed endotheliummodification caused by a vitamin
D direct effect (Sakurai et al., 2014; Prabhakar et al., 2015);
and (3) to white matter hyper intensities (WMHs), lacunas and
microbleeds in elderly with amnestic mild cognitive impairment
(Sakurai et al., 2014; Chung et al., 2015). However, very few data
are available regarding the vitamin D status in patients with pure
sVAD (Prabhakar et al., 2015). Prabhakar et al. (2015) reported
that hypertension and vitamin D deficiency considerably increase
the odds of VaD (Prabhakar et al., 2015). On the other hand,
a very recent study (Olsson et al., 2017) failed to show an
association between baseline vitamin D-status and long-term risk
of dementia or cognitive impairment over an 18 years period of
time.
Therefore, the purposes of our cross-sectional study are to
assess:
1. The differences in vascular risk factors and vitamin D-OH25
levels among groups of sVAD, AD, and healthy controls.
2. The association of folate, B12, homocysteine, and vitamin D
with sVAD/AD.
SUBJECTS’ CHARACTERISTICS
We conducted a cross-sectional study in a neurological group of
patients, affected by AD and sVAD and compared their results
with a normal healthy age population. From June 1st 2012 to
June 1st 2015 a total of 543 cases were included in the study.
87 men and women had, suffering from Alzheimer’s Disease,
according to NINDCS-ADRDA (McKhann et al., 1984) criteria
and the DSM-V (Fifth Edition), and 456 patients suffering from
subcortical vascular dementia, in accordance with the NINDS-
AIREN criteria (Chui et al., 1992; Román et al., 1993, see data
and literature in Olsson et al., 2017). AD subjects had to show
on brain MRI the pattern of hippocampal atrophy, and of the
temporoparietal and precuneus regions (Weinstein et al., 1993).
sVaD was diagnosed when the CT/MRI scan showed moderate
to severe ischemic white matter changes and at least one lacunar
infarct (Erkinjuntti et al., 1987; Marshall et al., 2006). As well
accepted by literature (see data in Kim et al., 2014) all the patients
had severe white matter hyperintensities on MRI, defined as
peri-ventricular white matter hyperintensities, localized around
the lateral ventricles or white matter hyperintensities, within the
deep white matter (see data in Fazekas et al., 1987; Cleutjens
et al., 2017). Brain CT-scans or MRI images were assessed
independently by the neurologist (RM), after the radiologist’s
opinion. Brain CT-scans or MRI images were available for all the
543 patients; 362 patients did MRI studies, 181 did CT scans; 298
patients did CT plus MRI. A neurologist (RM) revised all the
imaging, employing the Blennow scale for CT scans (Blennow
et al., 1991; Wallin and Blennow, 1991) and the Scheltens scale
for MRI imaging (Scheltens et al., 1993) in accordance with
parameters of recent literature (Kim et al., 2014). There was
93.8% inter-rater agreement for the independent assessment of
the scans (kappa= 0.79). Patients were not included in the study
if they showed signs of normal pressure hydrocephalus, previous
brain tumors, and previous diagnosis of major cerebrovascular
disease, white matter lesions, caused by different specific
etiologies, such as multiple sclerosis, collagen vascular disease,
and genetic forms of vascular dementia (such as CADASIL
or CARASIL). Patients with previous major psychiatric illness
(i.e., schizophrenia, bipolar disorders, psychosis, compulsive-
obsessive disorders, etc.) or central nervous system disorders and
alcoholism were excluded too.
Exclusion criteria were the absence of an informed caregiver,
unavailability of neuro-radiological examination, and/or the
assumption of psychotropic drugs within 2 months prior to the
clinical assessment. Seven patients were excluded by the lack of a
sufficiently informed caregiver and 18 because they had assumed
psychotropic drugs during the 2 months prior to our assessment.
Our control group was composed by healthy subjects,
relatives, or caregivers of the patients, with no history
of cerebrovascular diseases or degenerative disorders, who
voluntarily accepted to take part in the study, matched for age,
gender and educational level.
Study subjects underwent a standardized baseline
assessment that included a detailed history, a physical
examination, laboratory tests, and psychiatric evaluations.
The physical examination included cardiac and blood
pressure examination, peripheral pulses, retinal vessel,
electrocardiographic evaluation. All patients were followed-
up with periodical neurological and neuropsychological
examinations. The present study was conducted in accordance
with the Declaration of Helsinki and with the Ethics
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Guidelines of the Committee of the University-Hospital of
Trieste, which approved it, and written informed consent
was obtained from all the participants or from their
caregivers.
METHODS
Patients with AD were grouped in Group A while patients with
sVAD were assigned to Group B; controls were Group C. The
main outcomes of the study for the AD and sVAD patients
were: (1) global performance, assessed using the Mini-Mental
State Examination (Folstein et al., 1975); (2) Frontal Assessment
Battery (FAB; Dubois et al., 2000); (3) global behavioral
symptoms, assessed by the Neuropsychiatric Inventory, NPI
(Cummings et al., 1994); and (4) the caregiver stress, assessed
by the Relative Stress Scale, RSS (Kinney and Stephens, 1989).
Demographic details were registered for all the study subjects. All
the patients and controls attended the LABS tests at the Hospital
service, in order to reduce potentially different lab methods or
different value parameters.
Hypertension was defined as diastolic blood pressure (DBP)
≥ 90mm Hg and/or systolic blood pressure (SBP) ≥ 140
mm Hg. Diabetes mellitus was defined as venous plasma
glucose concentration of ≥ 120 mg/dl after an overnight fast
(Cummings et al., 1994). Glycated Hemoglobin (HbA1c) results
have been aligned to the assay used in the Diabetes Control
and Complications Trial (DCCT), expressed as a percentage
(DCCT-HbA1c); non-diabetic “normal” range being 4–5.6%;
5.5–6.5 high risk of diabetes; more than 6.6% as having
diabetes (WHO, IDF, 2006; Nathan et al., 2008; Weykamp,
2013). Fasting venous blood samples were collected, centrifuged
immediately and stored at −80◦C for further laboratory
analysis. Clinical laboratorymeasurements, including serum total
cholesterol, triglycerides, and high-density lipoprotein (HDL)
cholesterol, have been determined enzymatically and low-density
lipoprotein (LDL) cholesterol was calculated using Friedewald’s
formula (Friedewald et al., 1972). Serum levels of 25(OH)D
were measured using enzyme immuno-assay kits (DIAsource
Immunoassay S.A. Belgium) and quality control materials
provided by the manufacturer. As Prabhakar et al. (2015) we
employed the National Osteoporosis Society (NOS; Aspray et al.,
2014) and therefore, subjects were categorized into Vitamin D
deficiency [25(OH)D: ≤ 12 ng/ml], insufficiency [25(OH)D: 12–
20 ng/ml] and sufficiency [25(OH)D: N 20 ng/ml] groups.
In order to have a complete evaluation of calciummetabolism,
we tested at the same time the level of calcium and PTH. The level
of folate, vitamin B12 levels and Homocysteine were also tested
to obtain specific measures of vascular risk factors.
Statistical Analysis
Statistical analysis was performed with SPSS statistics 17.0 (SPSS,
version 17.0). The difference in baseline characteristics between
AD and sVAD and controls was assessed by ANOVA test for
categorical variables; in case the ANOVA results were found
significant, the multiple comparison analysis was also done
by and the Tukey Test, to examine those two groups which
were significantly different for each other. The multinomial
logistic regressionmethod was applied to analyze the relationship
between disease status (AD, sVAD and control) considering
them as dependent variable (non-metric) and age (metric),
sex (non-metric), Hb1Ac, Cholesterol, and lipid parameters,
calcium, PTH, vitamin D-OH25, folate, vitamin B12, and
Homocysteine (all metric) as independent variable. The utility of
present analysis (Multinomial Logistic regression) was assessed
by classification accuracy, which compares the predicted disease
group based on logistic model to the actual disease group
(which is the value for dependent variable). Univariate odds
ratios and 95% confidence intervals were estimated by binary
logistic regression analysis. Spearmann’s rank correlation analysis
was calculated for the demographic variable. P ≤ 0.05 were
considered statistically significant. Results are presented as mean
with standard deviations, and p-values are presented where
appropriate.
RESULTS
Eighty-seven AD patients and 456 sVAD patients were enrolled
in the study. One AD patient and five sVAD patients died during
the 12-months follow-up; therefore, 86 AD patients and 449
sVAD patients completed the study. Baseline neuropsychological
characteristics of the study groups are presented in Table 1.
The demographic variables i.e., age and gender were not
significantly associated with the dementia status in both AD
and sVAD. The demographic variables (age and gender) were
not significantly associated with the dementia status in both AD
and sVAD. One way analysis of variance (ANOVA) method was
applied to explore the statistical significant difference among
mean value in three groups (AD, sVAD, and control, Table 2).
Four of the different biochemical variables (low folate and
vitamin B12, low vitamin D-OH25, and high homocysteine)
studied were significantly different (p < 0.001) in three groups
(Table 2), which suggested that at least one average out of
the three was statistically different than the other (Table 3); to
explore such group, the multiple comparison analysis was done
by Tukey test (Table 4). In AD group, mean vitamin D-OH 25
values (10.8 ± 1.05)were significantly lower than control (18.7
± 3.05), mean folate levels (2.4 ± 0.3) were significantly lower
than control (6.4 ± 0.2), mean vitamin B12 levels (129 ± 23.2)
were significantly lower than controls (249 ± 13.2) and mean
homocysteine levels were significantly higher (18.3 ± 3.5) than
controls (11.1± 3.5).
In sVAD group, mean vitamin D-OH 25 values (9.1 ± 1.09)
were significantly lower than control (18.7 ± 3.05), mean folate
levels (1.9± 0.5) were significantly lower than control (6.4± 0.2),
mean vitamin B12 levels (111 ± 26.2) were significantly lower
than controls (249 ± 13.2) and mean homocysteine levels were
significantly higher (23.5± 3.4) than controls (11.1± 3.5).
According to the NOS criteria (Aspray et al., 2014) we have
found that there is a very significant difference in the prevalence
of vitamin D-OH 25 deficiency and insufficiency between the
three groups (Table 3). In AD population, 14% is deficient of
vitamin D-OH25, 79% is insufficient, and only 7% is sufficient;
in sVAD population, 11% is deficient of vitamin D-OH25, 86%
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TABLE 1 | Neuropsychological characteristics of study population (mean and SD in brackets).
Characteristics Group A Group B Group C F chi2 value DF p-value
Age 77.9 ± 2.01 75.65 ± 6.54 76.4 ± 2.3 2.66 2.24 0.73
MMSE score 19.4 (2.3) 24.2 (3.5) 27.9 (1.1) 0.71 2.157 0.01
FAB score 9.3 (2.5) 8.4 (1.3) 10.6 (1.2) 0.87 2.3 0.01
NPI score 20.3 (4.6) 16.1(3.2) 7.2 (3.1) 0.75 2.43 0.01
RSS score 42.3 (6.7) 27.3 (3.5) 8.1 (3.2) 0.89 2.02 0.01
TABLE 2 | Comparison of mean value of age, gender, educational level, various biochemical parameters in AD, sVAD, and controls.
Variable (Normal values) Group A (86) Group B (449) Group C (567) F chi2 value DF p-value
Age 77.9 ± 2.01 75.65 ± 6.54 76.4 ± 2.3 2.66 2.24 0.73
Gender M/F 41/45 193/256 197/370 0.79 2 0.68
Educational level (years) 7.7 ± 3.4 8.1 ± 1.22 8.0 ± 0.9 0.67 3.11 0.45
Hb1ac (%) 6.1 ± 0.3 6.7 ± 0.7 5.6 ± 0.4 0.79 2.31 0.79
Cholesterol (mg/dl) 197.4 ± 34.6 207.5 ± 21.3 186.4 ± 24.6 0.67 2.251 0.75
Trygliceridis (mg/DL) 139.5 ± 23.9 129.3 ± 25.6 99.5 ± 34.2 0.87 2.13 0.67
HDL (mg/dl) 35.7 ± 12.1 31.1 ± 7.2 39.1 ± 14.1 0.67 2.45 0.43
LDL (mg/dl) 133.8 ± 13.4 150.5 ± 12.2 127.4 ± 7.4 0.87 2.65 0.37
Calcium (8.610.5 mg/dl) 9.8 ± 1.1 10.1 ± 0.4 11.2 ± 2.5 0.65 2.31 0.43
PTH (12–72 pg/ml) 39 ± 2.3 41.3 ± 2.7 37 ± 1.6 0.76 2.11 0.34
Vitamin D-OH 25 (30–100 ng/ml) 10.8 ± 1.05 9.1 ± 1.09 18.9 ± 3.05 2.66 2.251 0.01
Folate (3.89–26.0 ng/ml) 2.4 ± 0.3 1.9 ± 0.5 6.4 ± 0.2 0.71 2.157 0.01
Vitamin B12 (205–870 pg/ml) 129 ± 23.2 111 ± 26.2 249 ± 13.2 2.09 2.35 0.04
Homocysteine (3–15 mcmol/l) 18.3 ± 3.5 23.5 ± 3.4 11.1 ± 3.5 5.77 2.41 0.01
is insufficient and only 3% is sufficient; whereas, in a healthy old
population, even considering the declared cases of osteoporotic
patients, only 0.17% is deficient of vitamin D-OH25, 24% is
insufficient and 76% is sufficient. According to our laboratory
cut-off scores, we have found that there is very significant
difference in the prevalence of high values of homocysteine
(16–20 mcmol/L) and very high levels of homocysteine (21–30
mcmol/L) between the three groups (Table 3). In AD population,
74.8% has high levels of homocysteine, 15.1% has very high levels
of it and 11% is in normal range; in sVAD population, 67.1%
has high levels of homocysteine, 21.8 % has very high values,
and only 5.1% is in normal range; whereas in a healthy old
population, only 15.1% has high levels of homocysteine, 84.8%
is in normal range and 0% has very high levels of it. Considering
our laboratory cut-off scores, we have found that there is a very
significant difference in the prevalence of low levels of folate (2–
3.88 ng/ml) and very low levels of folate (0.5–2.0 ng/ml) between
the three groups (Table 3). In AD population, 90.7% has low
levels of folate, 2.3% has very low levels of it and 7% is in normal
range; in sVAD population, 47.1% has low levels of folate, 49.6%
has very low values of it, and only 8.7% is in normal range;
whereas, in a healthy old population, only 11.1% has low levels
of folate, 0.2% has very low levels of it, and 88.7% is in normal
range. Considering our laboratory cut-off scores, we also have
found that there is a very significant difference in the prevalence
of low levels of vitamin B12 (100–204 pg/ml) and very low levels
of vitamin B12 (50–99 ng/ml) between the three groups (Table 3).
In AD population, 88.4% has low levels of vitamin B12 and 11.6%
is in normal range; in sVAD population, 70.7% has low levels of
vitamin B12 and 29.3% is in normal range; whereas, in a healthy
old population, only 25.9% has low levels of vitamin B12, and
74.1% is in normal range. Nobody reported very low levels of
vitamin B12.
The univariate regression analysis reveals crude odds ratio for
the association between AD and vitamin D insufficiency of 3.4
(95% CI: 10.93–13.56), p = 0.05 and vitamin deficiency of 5.6
(95% CI: 8.93–11.56), p = 0.023; there is an odd ratio for the
association between AD and low levels of folate of 3.7 (95% CI:
2.1–3.4), p = 0.047 and very low levels of folate of 4.9 (95%
CI: 1.1–2.1), p = 0.027; there is a odds ratio for the association
between AD and low levels of vitamin B12 of 3.1 (95% CI: 112.1–
203.4), p = 0.046; there is odds ratio for the association between
AD and high levels of homocysteine of 4.5 (95% CI: 18.1–19.4),
p = 0.036 and of 5.9 with very high levels of homocysteine (95%
CI: 20.1–23.4), p= 0.016.
The univariate regression analysis reveals crude odds ratio
for the association between sVAD and vitamin D insufficiency
of 4.1 (95% CI: 11. 3–12.5), p = 0.034 and vitamin deficiency
of 6.7 (95% CI: 7.3–9.6), p = 0.01; there is an odd ratio for the
association between sVAD and low levels of folate of 4.1 (95% CI:
2.0–2.9), p= 0.03and very low levels of folate of 5.9 (95% CI: 1.1–
2.1), p = 0.01; there is a odds ratio for the association between
sVAD and low levels of vitamin B12 of 3.9 (95% CI: 101.1–163.4),
p = 0.041; there is odds ratio for the association between sVAD
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TABLE 3 | Comparison of mean value of vitamin D-OH, folate, vitamin B12, and homocysteine (divided by different levels) parameters in D, sVAD, and controls.
Group A (86) Group B (449) Group C (567) F chi2 value DF P-value
Vitamin D-OH25 deficiency (≤ 12 ng/ml) 12 (14%) pts 49 (11%) pts 1 (0.17%) pts
8.1 (2.9) ng/ml 4.5 (2.1) ng/ml 11.1 (1.1) ng/ml 0.67 2.25 0.01
Vitamin D-OH25 insufficiency (12-20 ng/ml) 68 (79%) pts 387 (86%) pts 134 (24%) pts
15.7 (2.1) 12.1 (9.33) 19.1 (2.1) 0.87 2.13 0.01
Vitamin D-OH25 sufficiency (≥20 ng/ml) 6(7%) pts 13 (3%) pts 432 (76%) pts
23 (2.7) 21 (1.9) 29.4 (2.6) 0.71 2.6 0.43
Homocysteine (3-15 mcmol/l) 10 (11%) pts 23 (5.1%) pts 481 (84.8%) pts
10.7 (2.9) 11.1 (1.3) 8.4 (2.9) 0.81 2.1 0.47
Homocysteine (16–20 mcmol/l) 63 (74.8%) pts 301 (67.1%) pts 86 (15.1%) pts
18.5 (2.1) 19.3 (1.7) 17.1 (2.1) 0.84 2.6 0.05
Homocysteine (21–30 mcmol/L) 13 (15.1 %) pts 125 (21.8%) pts 0 pts
24.3 (2.1) 26.7 (2.5) 0 0.8 2.1 0.01
Folate (3.89–26 ng/ml) 6 (7%) pts 39 (8.7%) pts 503 (88.7%) pts
9.7 (1.1) 8.5 (2.3) 9.1 (1.7) 0.67 2.11 0.47
Folate (2–3.88 ng/ml) 78 (90.7%) pts 187 (41.7%) pts 63 (11.1%) pts
2.9 (1.2) 1.7 (2.3) 3.1 (1.0) 0.81 2.27 0.01
Folate (0.5–2.0 ng/ml) 2 (2.3%) pts 223 (49.6%) pts 1 (0.2%) pts
1.1 (20.7) 0.8 (1.1) 1.2 80.3) 0.81 2.1 0.01
Vit. B12 (205–870 PG/ML) 10 (11.6%) pts 132 (29.3%) pts 420 (74.1%) pts
264 (12.5) 251 (13.1) 305 (23.1) 0.86 2.6 0.45
Vit. B12 (100–204 PG/ML) 76 (88.4%) pts 317 (70.7%) pts 147 (25.9%) pts
125.4 (11.3) 102.6 (23.1) 167.4 (23.1) 0.59 2.6 0.05
Vit. B12 (50–99 PG/ML) 0 pts 0 pts 0 pts
0 0 0 na na na
and high levels of homocysteine of 5.9 (95% CI: 17.1–19.7), p =
0.01 and of 6.1 with very high levels of homocysteine (95% CI:
23.1–33.4), p= 0.016.
Table 5 shows the relationship of the disease state (AD
and sVAD) with age, gender, vitamin D-OH25, folate, vitamin
B12, and homocysteine levels. The presence of a relationship
between them was checked based on the statistical significance
of the final model chi-square and existence of a relationship
was established. Out of the six considered independent variables,
vitamin D-OH 25 levels, folate, and homocysteine had significant
contribution toward AD and sVAD groups. Moreover, the
regression coefficient (B) for vitamin D-OH25 was−0.46 for AD,
indicating that the increase of vitamin D-OH 25 decreased the
likelihood of dementia in AD group, with an exponential B value
of 0.82 (95% CI: 2.5–10.11), which implies that for an increase
of vitamin D-OH 25 levels the odds of having AD decreased by
18%; the regression coefficient (B) for folate was −0.88 for AD,
indicating that the increase of folate decreased the likelihood of
dementia in AD group, with an exponential B value of 0.91 (95%
CI: 2.1–9.1), which implies that for an increase of folate levels the
odds of having AD decreased by 9%; the regression coefficient
(B) for homocysteine was + 0.57 for AD, indicating that the
decrease of homocysteine decreased the likelihood of dementia
in AD group, with an exponential B value of 0.85 (95% CI: 2.1–
9.1), which implies that for a decrease of homocysteine levels the
odds of having AD decreased by 15%.
The regression coefficient (B) for vitamin D-OH25 was−0.39
for sVAD, indicating that the increase of vitamin D-OH 25
decreased the likelihood of dementia in AD group, with an
exponential B value of 0.79 (95% CI: 2.0–17.1), which implies
that for an increase of vitamin D-OH 25 levels the odds of
having sVAD decreased by 21%; the regression coefficient (B) for
folate was −0.77 for sVAD, indicating that the increase of folate
decreased the likelihood of dementia in sVAD group, with an
exponential B value of 0.89 (95% CI: 2.1–8.7), which implies that
for an increase of folate levels the odds of having sVAD decreased
by 11%; the regression coefficient (B) for homocysteine was
+0.23 for sVAD, indicating that the decrease of homocysteine
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TABLE 4 | Multiple comparison analysis (Tukey test) of various biochemical
parameters in AD, sVAD, and controls.
Variable Mean Diff. SE of mean Diff. p-value
VIT. D-OH-25
A vs. C −7.9 −2.01 0.01
B vs. C −9.6 −1.96 0.01
FOLATE
A vs. C −4 −0.1 0.01
B vs. C −4.5 −0.3 0.01
VIT. B12
A vs. C −120 −10.1 0.01
B vs. C −138 −13-0 0.01
HOMOCYSTEINE
A vs. C +7.2 0.4 0.01
B vs. C +12.4 0.1 0.01
decreased the likelihood of dementia in sVAD group, with an
exponential B value of 0.8 (95% CI: 2.1–13.4), which implies that
for an increase of homocysteine levels the odds of having sVAD
decreased by 20%.
In present analysis, the classification accuracy rate of logistic
model was 57.1% which was greater than the proportional
by chance accuracy; the criteria for classification accuracy was
satisfied.
In addition, serum 25(OH)D levels were found to be
significantly and directly correlated with low levels of folate in the
vitamin D-deficient group (Spearmann’s correlation coefficient,
r = 0.7 and 0.9, p < 0.01, respectively for Group A and B),
and there is significant correlation between low levels of vitamin
B12 in the vitamin deficient group (Spearmann’s correlation
coefficient, r = 0.8 and 0.9, p < 0.01, respectively for Group A
and B), and finally, there is significant correlation with higher
levels of homocysteine in the vitamin deficient and in the vitamin
insufficient groups (Spearmann’s correlation coefficient, r = 0.75
and 0.89, p < 0.01, respectively for Group A and B in the
deficiency; Spearmann’s correlation coefficient, r = 0.69, p <
0.05 and 0.71, p < 0.05, respectively for Group A and B in the
insufficient).
DISCUSSION
This study was aimed to answer the questions specified in the
introduction and namely whether alteration on the serum levels
of folate, B12, homocysteine, and vitamin D may be related to
neurodegenerative or vascular damage and our results are in line
with previously reported studies (Friedewald et al., 1972; Folstein
et al., 1975; McKhann et al., 1984; Erkinjuntti et al., 1987; Fazekas
et al., 1987; Kinney and Stephens, 1989; Blennow et al., 1991;
Wallin and Blennow, 1991; Chui et al., 1992; Román et al., 1993;
Scheltens et al., 1993; Weinstein et al., 1993; Cummings et al.,
1994; Dubois et al., 2000;Marshall et al., 2006;Moretti et al., 2006;
WHO, IDF, 2006; Nathan et al., 2008; Weykamp, 2013; Aspray
et al., 2014; Kim et al., 2014; Sakurai et al., 2014; Chung et al.,
2015; Prabhakar et al., 2015; Cleutjens et al., 2017; Olsson et al.,
2017).
We found that both A and B groups have lower folate and
vitamin B12 levels and a higher homocysteine, even if more
pronounced in sVAD than in AD. Of notice was the data obtained
with vitamin D-OH 25 level: we have established that 93% of our
AD patients and 97% of our sVAD patients suffered either from
deficiency or from insufficiency of vitamin D-OH 25. Moreover,
we found that for an increase of vitamin D-OH 25 levels the odds
of having AD decreased by 18%, for an increase of folate levels
the odds of having AD decreased by 9% and for a decrease of
homocysteine levels the odds of having AD decreased by 15%.
In sVAD we found that for an increase of vitamin D-OH 25
levels the odds of having sVAD decreased by 21%, for an increase
of folate levels the odds of having sVAD decreased by 11% and
for an increase of homocysteine levels the odds of having sVAD
decreased by 20%.
Our study has several limitations:
1. It is a single-center study
2. It has been designed as a cross-sectional study
3. The number of patients is small to interfere
4. It has no pathological confirm
It has some strengths:
1. All the patients can be fully examined
2. All the patients attended neuroimaging and
neuropsychological evaluation
3. We have examined two distinct dementing conditions, mainly
degenerative (AD) and vascular, related to small vessel disease
pathologies (sVAD)
4. We have a healthy old control group
5. For the first time, we produced data concerning the
superimposing effects of homocysteine high levels and low
vitamin D-OH 25.
Our results seem to have some accordance with many other in
literature (Afzal et al., 2014; Sakurai et al., 2014; Chung et al.,
2015; Prabhakar et al., 2015) as far as vitamin D-OH low levels,
but not with a recent one (Olsson et al., 2017). It also seems in
accordance with many other as far as homocysteine and folate
(see data and literature in McCully, 1969; Ueland et al., 2000;
Hogervorst et al., 2002; Moretti et al., 2017) but not with many
other (Homocysteine Studies Collaboration, 2002; Obeid and
Herrmann, 2006; Miles et al., 2016).
The novelty of our work is that we report the parallel effect
of two controversial factors: homocysteine and vitamin D in
two different dementing condition, AD and sVAD, and it seems
that the two variables create a detrimental effect, which seems
to promote the neural pathology, more evident in vascular
condition.
How can vitamin D-OH and homocysteine influence the
neural system? Do they act as neurodegenerative promoters or
as pure vascular damage factors?
Although homocysteine and vitamin D-OH 25 are different
from biochemical and structural properties, their activity is
surprisingly similar. The accumulation of homocysteine and
the deficiency of vitamin D-OH are both toxic to neuronal
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TABLE 5 | Summary of multinomial logistic regression analysis.
Variable Univariate association Regression coefficient (B) SE p-value EXP (B) 95% CI for exponential (B)
OR 95% CI p-value
Dependent Independent
AD Age 1.1 1.1–2.3 0.76 0.023 0.015 0.6 1.006 0.9–1.03
Sex 1.3 1.1–2.1 0.67 0.066 0.28 0.9 1.1 0.5–0.93
Vit-D-OH-25 4.5 4.5–7.1 0.023 −0.46 0.12 0.01 0.82 2.5–10.11
Folate 4.2 2.1–5.7 0.05 −0.98 0.17 0.01 0.91 2.1–9.1
B12 1.8 1.2–4-5 0.45 −0.97 0.65 0.7 0.98 1.3–4.1
Homocysteine 5.2 2.1–3.4 0.01 +0.57 0.12 0.01 0.85 2.7–10.4
sVAD Age 1.3 1.4–2.7 0.81 0.016 0.022 0.45 0.98 0.94–1.07
Sex 1.2 1.6–2.2 0.61 0.297 0.43 0.37 1.2 0.57–0.93
Vit-D-OH-25 5.7 2.5–6.1 0.01 −0.39 0.12 0.01 0.79 2.0–17.1
Folate 5.2 2.1–5.9 0.01 −0.77 0.23 0.01 0.89 2.1–8.7
B12 2.1 1.2–7.1 0.074 −0.67 0.02 0.8 0.7 1.2–4.7
Homocysteine 5.9 1.9–8.4 0.01 +0.23 0.01 0.01 0.8 2.1–13.4
cells. They might affect neuronal plasticity (Streck et al.,
2003), with different mechanisms in early or in adult life, and
improve neurodegeneration (Obeid and Herrmann, 2006), alter
brain energy productions mechanisms (Streck et al., 2003),
potentiate inflammation (Lazarewicz et al., 2003; Herrmann
et al., 2006) and reduce the endothelium response to oxidation
processes (Lazarewicz et al., 2003; Streck et al., 2003; Herrmann
et al., 2006). Homocysteine regulates calcium inflow, via the
activation of group I metabotropic glutamate receptors (Lipton
et al., 1997; Lazarewicz et al., 2003; Robert et al., 2005;
Herrmann et al., 2006; Obeid and Herrmann, 2006), and this
has a relevance in the induction of brain lipid peroxidation
process, and expanding the neural calcium-related apoptosis
mechanism (Blom and Smulders, 2011).Moreover, homocysteine
accumulation has an amyloidogenic effect by inducing the
endoplasmic reticulum protein HERP, which potentiates the
c-secretase activity and enhances the accumulation of AB1-
40 in the brain (Mok et al., 2002; Seshadri et al., 2002).
Homocysteine also increases the neural vulnerability to the
damage created by amyloid accumulation (Morris, 2003).
Hyper-homocystenemia upregulates PS1 genes, promoting a
hypomethylation of PPM1 (Leulliot et al., 2004), causing,
therefore, a hyperphosphorilation of tau protein, which seems
to potentiate the microtubules transport mechanism. The
activation of caspase-3 by hyperhomocystenemia promotes the
accumulation of amyloid on smooth muscle cells of small vessel
disease (Leulliot et al., 2004; Chun et al., 2016), which leads
to a dysregulation of cerebral blood flow, commonly observed
in AD and in vascular dementia. Higher homocysteine levels
can be considered as an independent risk factor for moderate
to severe leukaraiosis in patients with AD (Pushpakumar et al.,
2014; Zhou et al., 2014). Moreover, homocysteine metabolism is
regulated by the redox potential in the cell (Blom and Smulders,
2011; Pushpakumar et al., 2014; Zhou et al., 2014), by disruption
of the trans-sulfuration pathway (Seshadri et al., 2002; Obeid
and Herrmann, 2006; Blom and Smulders, 2011). Homocysteine
is a precursor of hydrogen sulfide (H2S), which revealed to
be a potent vasodilator and it regulates the vessel diameter, it
seems to protect the endothelium from redox stress and chronic
inflammation (Pushpakumar et al., 2014; Zhou et al., 2014).
The accumulation of homocysteine can cause a reduction in
nitric oxide synthesis and potentiate oxidative endothelium stress
(Pushpakumar et al., 2014; Zhou et al., 2014).
When we consider vitamin D, the results are surprisingly
similar. Animal models demonstrated alterations in fetal
and adult animal models induced by a deficiency of vitamin
D-OH 25. Vitamin D modulates different processes, such
as neurogenesis, cell proliferation, differentiation, and
neurotransmitter metabolism (Eyles et al., 2013, 2014; Cui
et al., 2015). By exposing fetal animals to vitamin D deficiency,
an evident alteration of dopamine and NMDA circuitries can
be observed, with clear consequences for altered behavior,
memory and motor assessment (Becker et al., 2005; Turner
et al., 2013; Eyles et al., 2014; Cui et al., 2015; Overeem et al.,
2016). On the other hand, the exposition of previously normally
developed brains to vitamin D deficiency seems to result in
memory impairment, with major conduct alterations and with
less executive possibilities (Byrne et al., 2013). These brains have
a reduction of the glutamic acid decarboxylase (key enzymes
in gamma-aminobutyric acid (GABAergic inter-neurons), and
show decreased levels of glutamate and glutamine in brain
tissue (Byrne et al., 2013). In a key study (Brewer et al., 2001),
it was found that vitamin D protected rat primary hippocampal
cultures from excitotoxicity insults (i.e., glycine and NMDA).
Patch clamp studies found that, L-type voltage-dependent
calcium currents were reduced following incubation with
vitamin D (Brewer et al., 2001; Carlberg et al., 2005; Balden et al.,
2012; Byrne et al., 2013; Gezen-Ak et al., 2013; Suzuki et al., 2013;
Cui et al., 2015); therefore it has been hypothesized that vitamin
D-OH 25 might influence calcium inflow, and consequently
it can regulate dendritic cell functions and neural apoptosis
(Carlberg et al., 2005; Gezen-Ak et al., 2013; Suzuki et al., 2013;
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Cui et al., 2015). On the other hand, vitamin D deficiency has
been related to altered myocardial functions, associated with a
ventricular dilation and impaired electromechanical coupling
(O’Connell et al., 1997; Xiang et al., 2005; Simpson, 2011).
Much more stimulating is the endothelial cells expression of
the receptors for vitamin D; these receptors are up-regulated
under inflammation condition in endothelial cells (Xiang et al.,
2005; Bodyak et al., 2007; Wong et al., 2008) and vitamin D
analogs decrease endothelium adhesion molecules, and protect
against advanced glycation products (Young et al., 2011),
reduce vascular smooth muscle contractions and vascular
tone in hypertensive models, modulating the calcium influx
across endothelial cells (Manolagas et al., 1986; Danielsson
et al., 1996; Somjen et al., 2005; Wong et al., 2008; Oh et al.,
2009).
However, it cannot be denied that results in Literature,
concerning the two above-mentioned biochemical variables, are
wide-ranging, controversial and sometimes even contradictory.
In accordance with modern and recent approaches in
Literature, neuro-inflammation is the possible point in common
between the two factors. We support this idea and speculate
on the fact that low levels of vitamin D and high levels of
homocysteine, in co-existence, might lead to an altered response
to inflammation, and therefore predispose to microvascular
and endothelium damages. Different reports documented the
Th1 induced homocysteine inflammation response (Murr et al.,
2001), and it appears that higher levels of homocysteine can be
detected in chronic inflammatory conditions, even if vitamin B12
and folate are in range. Many studies documented that higher
levels of homocysteine are related to an increment of neopterin
and Il-6 (Bleie et al., 2007), which can be partially modulated
only by a correct implementation of folate. Thus, it has been
suggested that “an optimal folate status over-ride the influence
of immunostimulation on Th1 by Hcy” (Bleie et al., 2007). Li
et al. (2015) showed that an animal model induced hyper-Hcy
produced higher plasma levels of tumor necrosis factor alpha
(TNF-α) and Interleukin 1 beta (IL-1β) and therefore induced
a trigger of inflammation. These results have been confirmed
by many other reports (Yi-Deng et al., 2007; Krishna et al.,
2013; Zhou et al., 2014) which showed that higher levels of
Hcy promotes, in many different experimental conditions, the
activity of specific but different genes, implicates in methylation
process, and caused inflammation of the endothelium matrix
and atherosclerosis (Yi-Deng et al., 2007; Krishna et al., 2013;
Zhou et al., 2014). In different chronic medical conditions,
like Rheumatoid Arthritis (Essouma and Noubiap, 2015) higher
levels of homocysteine are more frequent than in the general
population, and that hyper-homocysteine in RA creates a chronic
condition of oxidative stress, prothrombotic induction, and,
indirectly, by the excess of ROS released, it up-regulates the
Nuclear Factor Kappa B, considered as one of “the master
regulator of the expression of inflammatory genes” (Essouma
and Noubiap, 2015; Ying et al., 2015). A very recent work has
demonstrated that cytokines released by microglia can activate
NF-KB signaling resulting in an enhanced expression of the
pro-inflammatory system, such as Toll-like receptors (TLR),
in particular, TLR2, 4 and 9 (Zhou et al., 2016). They are
hyper-expressed by microglia and directly activate NF-KB in
“in vitro-BV2 model” of PD (Zhou et al., 2016). Different
new studies pointed out the topic of inflammation as a strong
basis of many different neurodegenerative pathologies, like PD,
where in vitro specific models, like 6-OHDA- lesioned PC12
cells highly expressed COX2, IL-2 and TNF-alpha (Rong et al.,
2003; Xu et al., 2013). In the same in-vitro PD model, it has
been established the inflammatory mediator participation of a
nuclear receptor subfamily, the so-called NUR, involved as a
transcriptional factors, in all the process involving neuronal
development and in the response to inflammatory attacks (Rong
et al., 2003). In particular, Nur 77 acts as a potent modulator of
the macrophage and T cell response (as pointed out by Wei et al.,
2016), and indirectly promotes inflammation and mitochondrial
dysfunction and therefore causes apoptosis. In particular, there is
a well-documented increase of the cytosolic level of Nur 77, with
a well-described translocation from the nucleus to the cytosol,
following the oxidative stress in the PD in vitro-model (Gao
et al., 2016; Wei et al., 2016). Even in the vascular dementia
model, inflammation is claimed as a determinant factor: different
biomarkers have been claimed to be over-expressed, such as
CysC (Jonsdottir et al., 2013), which seems to be increased in
AD and in VAD patients, compared to healthy subjects, and
correlates with the severity of the disease (Chen et al., 2015).
In the same line, many other biochemical variables, such as
HDL, have found to be increased in plasma in AD and in
VAD patients. HDL probably promotes an anti-oxidative stress
response in damaged brain structures (Wen et al., 2017). Even
uric acid acts as a natural anti-oxidative stress factor (acting as
a possible disease modifier in MSA and PD) (Jin et al., 2010;
Yilmaz and Granger, 2010). It has been inflammatory process
plays a dominant role in the pathogenesis of brain ischemia
and contributes to stoke formation (Broughton B. R. et al.,
2013). Anoxia induces the production of reactive oxygen species
and an induction of ICAM1, VCAMS, Selectins, integrins on
endothelium leukocytes and platelets (Broughton B. R. S. et al.,
2013; Azizieh et al., 2016).
In the same line go all the most recent studies on vitamin
D-OH25 deficiency, in order to promote inflammation and
endothelium degeneration (Mangin et al., 2014; Na et al., 2014).
When considering all these results, it can be strongly
supported the hypothesis of combined and shared roles of
vitamin D and homocysteine in neurodegeneration and in
vascular and endothelium disruption.
CONCLUSIONS
The questions which we made at the very beginning have been
finally answered.
Many doubts remain; how do homocysteine and vitamin D
act to create damage? Do they potentiate neurodegeneration or
microvascular alteration?
We have observed that low levels of vitamin D are
more present in dementia populations, in degenerative
and in small-vessel types; these two groups share
hyperhomocystenemia, too; the combined presence of
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both factors is significantly higher in these two groups.
More studies will be needed to implement further
knowledge.
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